LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

78.99 0.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78

Max

79.78

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+7.95% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

13B

Ankstesnė atidarymo kaina

78.47

Ankstesnė uždarymo kaina

78.99

Naujienos nuotaikos

By Acuity

34%

66%

116 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-10 22:02; UTC

Uždarbis

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025-12-10 21:46; UTC

Uždarbis

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025-12-10 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025-12-10 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025-12-10 23:36; UTC

Rinkos pokalbiai

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025-12-10 23:20; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025-12-10 23:15; UTC

Uždarbis

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025-12-10 22:59; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025-12-10 22:45; UTC

Rinkos pokalbiai

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025-12-10 22:40; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 22:06; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 22:02; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:00; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025-12-10 21:53; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025-12-10 21:50; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-10 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 21:33; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025-12-10 21:32; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025-12-10 21:25; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025-12-10 21:16; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025-12-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025-12-10 21:15; UTC

Uždarbis

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

7.95% į viršų

12 mėnesių prognozė

Vidutinis 84.88 USD  7.95%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

15

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

116 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat